Kwangdong Pharmaceutical announced on the 4th that it has partnered with MSD Korea to jointly market “Capvaxive®,” a 21-valent pneumococcal conjugate vaccine for adults, in the domestic market. The two companies plan to begin full-scale joint marketing from the time of the vaccine’s launch in the first quarter of this year.

This collaboration is an expansion of the partnership between the two companies following their joint promotion of the human papillomavirus (HPV) vaccines “Gardasil” and “Gardasil 9.” Through this, they plan to further strengthen synergies in the domestic vaccine market.

Capvaxive is a newly designed vaccine aimed at preventing invasive pneumococcal disease (IPD) and pneumonia in adults, developed to reflect recent changes in adult infectious disease epidemiology (the field that analyzes the distribution and causes of diseases) and unmet medical needs. According to the approval, Capvaxive can be used in adults aged 18 years and older to prevent invasive disease and pneumococcal pneumonia caused by a total of 22 serotypes.

Choi Sung-won, CEO of Kwangdong Pharmaceutical, said, “This collaboration has further strengthened our vaccine portfolio. We will leverage Kwangdong Pharmaceutical’s sales network and expertise to support Capvaxive in rapidly establishing its position in the market.”

Albert Kim, Managing Director of MSD Korea, stated, “Based on more than 25 years of experience supplying adult pneumococcal vaccines in Korea, this collaboration will enable more adults to benefit from the prevention of pneumococcal diseases.”

Popular News